Zacks Investment Research upgraded shares of DYAX CORP (DYAX) from NEUTRAL to OUTPERFORM on October 30, 2012, with a target price of $3.30.
Dyax Corp is a biopharmaceutical company that has developed and patented a method that is used to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. The company is also using this method to identify compounds that could be used in purifying and manufacturing biopharmaceuticals and other chemicals. The company's phage display technology to rapidly and cost-effectively determine the potential medical uses of newly discovered proteins and genes and subsequently discover biopharmaceutical product candidates.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on DYAX CORP (DYAX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment